Ryvu Therapeutics S.A. (WSE:RVU)
Poland
· Delayed Price · Currency is PLN 24.25
-1.75 (-6.73%)
Apr 3, 2025, 4:00 PM CET
Ryvu Therapeutics Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 101.96 | 67.3 | 68.44 | 35.41 | 36.95 | Upgrade
|
| Other Revenue | - | - | - | 0 | - | Upgrade
|
| Revenue | 101.96 | 67.3 | 68.44 | 35.41 | 36.95 | Upgrade
|
| Revenue Growth (YoY) | 51.51% | -1.67% | 93.25% | -4.16% | 9.58% | Upgrade
|
| Cost of Revenue | 19.58 | 17.55 | 17.41 | 13.73 | 8.76 | Upgrade
|
| Gross Profit | 82.38 | 49.74 | 51.03 | 21.69 | 28.19 | Upgrade
|
| Selling, General & Admin | 183.59 | 123.46 | 84.55 | 64.35 | 50.51 | Upgrade
|
| Other Operating Expenses | 10.27 | 12.68 | 23.08 | 23.66 | 1 | Upgrade
|
| Operating Expenses | 204.35 | 147.12 | 120.53 | 100.57 | 63.89 | Upgrade
|
| Operating Income | -121.97 | -97.38 | -69.49 | -78.89 | -35.7 | Upgrade
|
| Interest Expense | -3.81 | -0.1 | -1.09 | -0.44 | -0.39 | Upgrade
|
| Interest & Investment Income | 9.13 | 13.83 | 1.15 | 0.06 | 0.22 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.21 | -4.9 | -0.83 | 0.02 | -0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.85 | -0 | 0 | 0 | - | Upgrade
|
| EBT Excluding Unusual Items | -111.01 | -88.54 | -70.27 | -79.25 | -35.99 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.13 | -3.57 | -8.93 | 0.29 | 5.36 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.01 | Upgrade
|
| Pretax Income | -111.14 | -92.11 | -79.2 | -78.96 | -30.62 | Upgrade
|
| Income Tax Expense | 0.3 | - | 4.59 | 0.12 | 1.07 | Upgrade
|
| Earnings From Continuing Operations | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade
|
| Net Income to Company | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade
|
| Net Income | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade
|
| Net Income to Common | -111.44 | -92.11 | -83.78 | -79.08 | -31.69 | Upgrade
|
| Shares Outstanding (Basic) | 23 | 23 | 18 | 18 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 23 | 18 | 18 | 17 | Upgrade
|
| Shares Change (YoY) | 0.97% | 24.75% | - | 9.48% | 4.98% | Upgrade
|
| EPS (Basic) | -4.82 | -4.02 | -4.56 | -4.31 | -1.89 | Upgrade
|
| EPS (Diluted) | -4.82 | -4.02 | -4.56 | -4.31 | -1.89 | Upgrade
|
| Free Cash Flow | -135.38 | -93.13 | 15.07 | -70.87 | -44.82 | Upgrade
|
| Free Cash Flow Per Share | -5.86 | -4.07 | 0.82 | -3.86 | -2.67 | Upgrade
|
| Gross Margin | 80.80% | 73.91% | 74.57% | 61.24% | 76.28% | Upgrade
|
| Operating Margin | -119.63% | -144.70% | -101.54% | -222.76% | -96.63% | Upgrade
|
| Profit Margin | -109.29% | -136.88% | -122.42% | -223.30% | -85.76% | Upgrade
|
| Free Cash Flow Margin | -132.78% | -138.39% | 22.01% | -200.12% | -121.28% | Upgrade
|
| EBITDA | -111.76 | -87.32 | -58.16 | -67.94 | -26.17 | Upgrade
|
| EBITDA Margin | -109.61% | -129.76% | -84.99% | -191.85% | -70.83% | Upgrade
|
| D&A For EBITDA | 10.22 | 10.05 | 11.33 | 10.95 | 9.53 | Upgrade
|
| EBIT | -121.97 | -97.38 | -69.49 | -78.89 | -35.7 | Upgrade
|
| EBIT Margin | -119.63% | -144.70% | -101.54% | -222.76% | -96.63% | Upgrade
|
| Revenue as Reported | 101.96 | 67.3 | 68.44 | 35.41 | 36.95 | Upgrade
|
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.